Heath Systems Regional Scientific Director
Madrigal Pharmaceuticals
Summary
The Heath Systems Regional Scientific Director (HSRSD) is a therapeutic and disease expert who develops on-going professional relationships with healthcare decision makers within defined regional payer organizations (e.g., health plans, PBMs, integrated delivery systems, large GI practices, specialty pharmacy) and other key health systems in the assigned region.
Job description
The HSRSD provides accurate information about Madrigal products and related disease areas, clinical science and HEOR/real-world research/evidence in a balanced and credible manner consistent with the regulatory environment and Madrigal’s ethical standards.
Serves as a resource for the Global Medical Affairs (GMA) management team on strategic planning and provides mentoring for other team members. Works closely with account executives and key account managers, as well as other field medical colleagues to address the scientific needs in the region.
The position reports to the Health Systems Senior Director East / West and is a remote field-based position. This region will cover CO, UT, AZ and NV with the ideal location being Denver, Salt Lake City, Phoenix or Las Vegas.
Key Responsibilities and Primary Activities
- Develops ongoing professional relationships with key decision makers in organized health systems to ensure access to medical and scientific information on Madrigal’s products, development programs and related disease area(s)
- Partners with the Market Access Region Account Director (RAD) and Key Account Director (KAD) teams to develop strategic account plans; execute medical activities in alignment with agreed plan
- Effectively communicates and coordinates with regional MSLs regarding medical and scientific support needs in key affiliated regional health systems – IDNs, GI practices and regional payers
- Serves as a resource for the Health Systems Senior and Executive Directors and other members of market access RAD and KAD organizations on other relevant strategic planning
- Provides support for HEOR activities led by HQ HEOR within regional accounts of responsibility
- Serves as a technical resource on questions raised by market access RAD and KAD team members
- Attends and supports scientific and medical meetings. Prepares planned post-meeting deliverables
- Supports the Senior and Executive Directors HS, with the HS team budget
- Compliant with applicable policies, procedures, and regulations
- Maintain a strong understanding of US regulations and compliance
- Ability to travel up to 30% including support of scientific meetings over weekends
Required Qualifications, Skills & Experience
- Clinical or scientific degree required (e.g., MD, PharmD, PhD, MS, MPH, etc.)
- 5+ years’ experience in IDN and payer space and the ability to develop peer-to-peer relationships with key decision makers; may be gained through working on the customer side or in an industry role working with these customers.
- Must demonstrate a thorough knowledge of payer and IDN organizational practices
- Thorough knowledge of clinical medicine, the managed market environment, Pharmacoeconomics, disease management, real-world evidence generation and medical research
- Business and market knowledge, including quality management, formulary management and pathway development/management
- Excellent interpersonal communication skills, strong presentation skills, ability to work with cross functional field account teams, strong personal integrity, collaborative mindset, and strong customer focus are necessary
- Must possess a thorough understanding of the FDA, OIG, HIPAA and other ethical guidelines, laws and regulations relevant to the pharmaceutical industry
- Must be able to organize, prioritize, and work effectively in a constantly changing environment, and have demonstrated project leadership abilities
- Proficiency in Microsoft Office Suite, virtual communication platforms (e.g., Zoom, Teams), and related Medical Affairs Systems (e.g. Veeva Vault, CRM tools)
Preferred Attributes
- Formal training in health economics or outcomes research
- Field based medical experience
- Liver and/or GI experience preferred, including non-viral liver disease
Requirements
- Clinical or scientific degree required (e.g., MD, PharmD, PhD, MS, MPH, etc.)
- 5+ years’ experience in IDN and payer space and the ability to develop peer-to-peer relationships with key decision makers
- Must demonstrate a thorough knowledge of payer and IDN organizational practices
- Thorough knowledge of clinical medicine, the managed market environment, Pharmacoeconomics, disease management, real-world evidence generation and medical research
- Business and market knowledge, including quality management, formulary management and pathway development/management
- Excellent interpersonal communication skills, strong presentation skills, ability to work with cross functional field account teams, strong personal integrity, collaborative mindset, and strong customer focus are necessary
- Must possess a thorough understanding of the FDA, OIG, HIPAA and other ethical guidelines, laws and regulations relevant to the pharmaceutical industry
- Must be able to organize, prioritize, and work effectively in a constantly changing environment, and have demonstrated project leadership abilities
- Proficiency in Microsoft Office Suite, virtual communication platforms (e.g., Zoom, Teams), and related Medical Affairs Systems (e.g. Veeva Vault, CRM tools)
Benefits
- Flexible paid time off
- Medical, Dental & Vision
- Life/Disability Insurance
- 401(k) Matching
- Equity
- Mental Health Benefits
- Employee Assistance Program
- Supplemental Life Insurance
- Legal Services
Company overview
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The company's lead product, Rezdiffra (resmetirom), is a once-daily, oral thyroid hormone receptor (THR)-β selective agonist that targets key underlying causes of MASH in the liver. Rezdiffra received FDA approval in 2024 as the first treatment for MASH with moderate to advanced liver fibrosis, representing a significant breakthrough in hepatology. Headquartered in Conshohocken, Pennsylvania, Madrigal is publicly traded on NASDAQ under the symbol MDGL. The company continues to advance its clinical development programs, including ongoing Phase 3 trials evaluating Rezdiffra for the treatment of compensated MASH cirrhosis. Madrigal's innovative approach addresses a critical unmet medical need in liver disease therapeutics.